Kathryn Shoemaker

University of Oxford — United Kingdom

Medicine · Health Sciences

12h-index2.0kcitations30works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(13), COVID-19 Clinical Research Studies(11), Pneumonia and Respiratory Infections(6), Antimicrobial Resistance in Staphylococcus(5), Vaccine Coverage and Hesitancy(4)

Publications29 total

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Mayo Clinic Proceedings Innovations Quality & Outcomes·2025Open Access
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study
Vaccines·2024· 2 citedOpen Access
Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial
European Respiratory Journal·2024· 16 citedOpen Access
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
The Lancet Microbe·2024· 6 citedOpen Access
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity
Frontiers in Immunology·2024· 2 citedOpen Access
Correction: Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia
Critical Care·2023Open Access
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
The Lancet Microbe·2023· 9 citedOpen Access
Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia
Critical Care·2023· 6 citedOpen Access
One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan
Vaccine·2023· 7 citedOpen Access
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Frontiers in Immunology·2023· 12 citedOpen Access
1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination
Open Forum Infectious Diseases·2022Open Access
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Critical Care·2022· 82 citedOpen Access
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Journal of Clinical Investigation·2022· 31 citedOpen Access
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study
Journal of Clinical Microbiology·2022· 11 citedOpen Access
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
International Journal of Infectious Diseases·2021· 30 citedOpen Access
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Nature Medicine·2021· 1.2k citedOpen Access
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
2021· 163 citedOpen Access
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
The Lancet Infectious Diseases·2021· 80 citedOpen Access
The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma
Journal of Allergy and Clinical Immunology·2021· 6 cited
1486. Phylogenetic and alpha toxin variant analyses of <i>Staphylococcus aureus</i> strains isolated from patients during the SAATELLITE study
Open Forum Infectious Diseases·2020Open Access
page 1 of 2Next →

Frequent Co-authors

Elizabeth J. Kelly(12), Omar Ali(11), Alexey Ruzin(11), Hasan S. Jafri(10), Tonya Villafana(9), Bruno François(9), Miguel Sánchez García(9), Susan Colbert(8), Terramika Bellamy(7), Philippe Eggimann(7), Leen Timbermont(7), Vincent Huberlant(7), Pierre‐François Dequin(7), Brett Jepson(6), Filip Dubovsky(6), Mark T. Esser(6), Thierry Boulain(6), Cédric Bretonnière(6), Jérôme Pugin(6), Ann R. Falsey(6)